STOCK TITAN

Kodiak Sciences (KOD) CEO awarded 175k performance-based options at $25

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kodiak Sciences Inc. reported that Chairman and CEO Victor Perlroth received a grant of stock options covering 175,000 shares of common stock. The options have an exercise price of $25.0000 per share and expire on March 17, 2036.

The award is performance-based. Vesting will be determined by the 30-day average stock price as of June 30, 2027, defined as the Performance Criteria Achievement Date. If the average price is less than $25.00, none of the options vest; at or above $25.00, one-third vests; above $30.00, two-thirds vests; and above $35.00, all 175,000 options vest, subject to Perlroth continuing as a service provider on that date.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PERLROTH VICTOR

(Last)(First)(Middle)
1250 PAGE MILL ROAD

(Street)
PALO ALTO CALIFORNIA 94304

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kodiak Sciences Inc. [ KOD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chairman and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$2503/18/2026A175,000 (1)03/17/2036Common Stock175,000$0175,000D
Explanation of Responses:
1. Shares subject to the performance-based option will vest as follows based on the 30-day average stock price as measured on June 30, 2027, the Performance Criteria Achievement Date (the "PCAD"). In the event the average stock price on the PCAD is (i) less than $25.00, then zero shares will vest, (ii) greater than or equal to $25.00, then one-third of the shares subject to the option will vest, (iii) greater than $30.00, then two-thirds of the shares subject to the option will vest; or (iv) greater than $35.00, then all the shares subject to the option will vest, subject to the Reporting Person's status as a Service Provider (as defined in the 2018 Equity Incentive Plan) on the PCAD.
/s/ David Peinsipp, Attorney-in-Fact for Victor Perlroth03/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kodiak Sciences (KOD) disclose about Victor Perlroth in this Form 4?

Kodiak Sciences reported that Chairman and CEO Victor Perlroth received a grant of stock options for 175,000 shares. These options are compensation, not an open-market purchase or sale, and their vesting depends on Kodiak’s stock price performance by June 30, 2027.

How many stock options did Kodiak Sciences (KOD) grant to its CEO?

Victor Perlroth was granted options covering 175,000 shares of Kodiak Sciences common stock. The options have a per-share exercise price of $25.0000 and give him the right, but not the obligation, to buy shares if vesting and other conditions are satisfied.

What are the performance vesting conditions for the Kodiak Sciences (KOD) CEO options?

Vesting depends on the 30-day average stock price on June 30, 2027. Below $25.00 no options vest; at or above $25.00 one-third vests; above $30.00 two-thirds vests; and above $35.00 all 175,000 options vest, subject to continued service.

What is the exercise price and expiration date of the Kodiak Sciences (KOD) CEO option grant?

The options granted to Victor Perlroth have an exercise price of $25.0000 per share and an expiration date of March 17, 2036. He can only exercise vested portions during this term, assuming the performance and service conditions are met.

Does this Kodiak Sciences (KOD) Form 4 show the CEO buying or selling shares in the market?

No, the Form 4 reflects a grant of stock options as compensation, coded as an acquisition (A), rather than a market purchase or sale. No open-market buying or selling of Kodiak Sciences common stock is reported in this filing.
Kodiak Sciences Inc.

NASDAQ:KOD

View KOD Stock Overview

KOD Rankings

KOD Latest News

KOD Latest SEC Filings

KOD Stock Data

1.35B
57.23M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
PALO ALTO